BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Funke U, Vugts DJ, Janssen B, Spaans A, Kruijer PS, Lammertsma AA, Perk LR, Windhorst AD. 11 C-labeled and 18 F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain: PET ligands for histamine receptors in the brain. J Label Compd Radiopharm 2013;56:120-9. [DOI: 10.1002/jlcr.3038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Li W, Wu X. Palladium-Catalyzed Carbonylative Synthesis of Benzoxazinones from N -( o -Bromoaryl)amides Using Paraformaldehyde as the Carbonyl Source. J Org Chem 2014;79:10410-6. [DOI: 10.1021/jo5020118] [Cited by in Crossref: 72] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
2 Finnema SJ, Scheinin M, Shahid M, Lehto J, Borroni E, Bang-Andersen B, Sallinen J, Wong E, Farde L, Halldin C, Grimwood S. Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology (Berl) 2015;232:4129-57. [PMID: 25921033 DOI: 10.1007/s00213-015-3938-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
3 Pittenger C. The histidine decarboxylase model of tic pathophysiology: a new focus on the histamine H3 receptor. Br J Pharmacol 2020;177:570-9. [PMID: 30714121 DOI: 10.1111/bph.14606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huang HL, Huang YC, Lee WY, Yeh CN, Lin KJ, Yu CS. 18F-glutathione conjugate as a PET tracer for imaging tumors that overexpress L-PGDS enzyme. PLoS One 2014;9:e104118. [PMID: 25111383 DOI: 10.1371/journal.pone.0104118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Janssen B, Vugts DJ, Funke U, Molenaar GT, Kruijer PS, van Berckel BN, Lammertsma AA, Windhorst AD. Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochim Biophys Acta 2016;1862:425-41. [PMID: 26643549 DOI: 10.1016/j.bbadis.2015.11.011] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
6 Lewis DY, Champion S, Wyper D, Dewar D, Pimlott S. Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical. PLoS One 2014;9:e115876. [PMID: 25542008 DOI: 10.1371/journal.pone.0115876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lu S, Siméon FG, Telu S, Cai L, Pike VW. The chemistry of labeling heterocycles with carbon-11 or fluorine-18 for biomedical imaging. Elsevier; 2020. pp. 241-384. [DOI: 10.1016/bs.aihch.2019.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Airas L, Rissanen E, Rinne JO. Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clin Transl Imaging 2015;3:461-73. [PMID: 27331049 DOI: 10.1007/s40336-015-0147-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
9 Airas L, Rissanen E, Rinne J. Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Mult Scler 2017;23:496-504. [PMID: 27760860 DOI: 10.1177/1352458516674568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
10 Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021;:1-68. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Siméon FG, Culligan WJ, Lu S, Pike VW. 11C-Labeling of Aryl Ketones as Candidate Histamine Subtype-3 Receptor PET Radioligands through Pd(0)-Mediated 11C-Carbonylative Coupling. Molecules 2017;22:E792. [PMID: 28498336 DOI: 10.3390/molecules22050792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
12 Dettori I, Gaviano L, Melani A, Lucarini L, Durante M, Masini E, Pedata F. A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Is Protective in a Rat Model of Transient Cerebral Ischemia. Front Pharmacol 2018;9:1231. [PMID: 30420807 DOI: 10.3389/fphar.2018.01231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schneider EH, Neumann D, Seifert R. Histamine H4-receptor expression in the brain? Naunyn-Schmiedeberg's Arch Pharmacol 2015;388:5-9. [DOI: 10.1007/s00210-014-1067-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hanyu M, Kawamura K, Takei M, Furutsuka K, Shiomi S, Fujishiro T, Ogawa M, Nengaki N, Hashimoto H, Fukumura T, Zhang M. Radiosynthesis and quality control of [ 11 C]TASP457 as a clinically useful PET ligand for imaging of histamine H 3 receptors in human brain. Nuclear Medicine and Biology 2016;43:679-84. [DOI: 10.1016/j.nucmedbio.2016.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
15 Zak A, Lemaire L, Chalon S, Chicheri G, Marzag H, Bodard S, Sérrière S, Routier S, Buron F, Vercouillie J. [18 F]-labeled positron emission tomography ligand for the histamine H4 receptor. J Labelled Comp Radiopharm 2021;64:363-72. [PMID: 34089268 DOI: 10.1002/jlcr.3929] [Reference Citation Analysis]
16 Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 2018;28:175-96. [PMID: 29334795 DOI: 10.1080/13543776.2018.1424135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
17 Franco Machado J, Silva RD, Melo R, G Correia JD. Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics. Molecules 2018;24:E49. [PMID: 30583594 DOI: 10.3390/molecules24010049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]